



It's a Done Deal

\$6,200,000



Follow-On

Sole Placement Agent

FEBRUARY 2024

ROTH MKM Acted as Sole Placement Agent for Revelation Biosciences Inc. (NASDAQ: REVB) in its \$6.2 Million Follow-On

For more information please contact:

Investment Banking

[James Antonopoulos](#)

Managing Director & Head of Healthcare Investment Banking
(646) 358-1906

jantonopoulos@roth.com

[Aparna Beeram](#)

Senior Vice President
Investment Banking
(646) 358-1912

abeeram@roth.com

Equity Capital Markets

[Aaron Gurewitz](#)

President & Head of
Investment Banking
(949) 720-5703

agurewitz@roth.com

[Nazan Akdeniz](#)

COO &

Transaction Information

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced the closing of a public offering of 1,365,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 2,730,000 shares of its common stock at an offering price to the public of \$4.53 per share and associated warrant. The warrants will have an exercise price of \$4.53 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The offering closed on February 05, 2024.

ROTH MKM acted as sole placement agent for the offering.

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including GEMINI-SSI as a prevention for hospital acquired infection,

Managing Director
Equity Capital Markets
(949) 720-5740
nakdeniz@roth.com

Lou Ellis

Managing Director
Equity Capital Markets
(949) 720-5739
lellis@roth.com

GEMINI-AKI as a prevention for acute kidney injury, and GEMINI-CKD for the treatment of chronic kidney disease. For more information on Revelation, please visit www.RevBiosciences.com. (Source: Company Website 2.5.24)

About ROTH MKM

ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information on ROTH MKM, please visit www.roth.com.

[About ROTH MKM](#) | [Investment Banking](#) | [Capital Markets](#) | [Institutional Sales & Trading](#)
[Research](#) | [Corporate Services](#) | [Corporate Access & Conferences](#) | [Press Room](#)

Date of Announcement: 2.8.24

The material, information and facts discussed in this announcement other than the information regarding ROTH MKM and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of Roth. Copyright 2024.

Roth Capital Partners, LLC

888 San Clemente Drive, Newport Beach CA 92660 | Member SIPC/FINRA | www.roth.com

